Beyond Fluid Replacement: How the PREEVEnT Trial Could Rewrite Burn Care Economics and Endothelial Science

Introduction: The PREEVEnT Trial – More Than a Clinical Question

On March 17, 2026, The Diane and Bruce Halle Arizona Burn Center at Valleywise Health announced the initiation of the Plasma Resuscitation Early for Evaluating Volume and Endotheliopathy of Thermal Injury (PREEVEnT) clinical trial (Source 1: [Primary Data]). The trial’s stated objective is to examine whether early plasma resuscitation improves outcomes for patients with life-threatening burn injuries (Source 1: [Primary Data]).

While framed as a clinical efficacy study, the trial’s design and endpoints position it as a potential inflection point for burn care protocols. The core thesis of this analysis is that PREEVEnT’s significance extends beyond immediate patient outcomes. Its true impact lies at the intersection of advanced trauma science, healthcare economic models, and the logistics of blood product supply chains. A shift in resuscitation paradigm would trigger cascading effects across these domains.

The Hidden Economic Logic: From Cheap Saline to Premium Plasma

The current standard of care for major burn resuscitation relies heavily on crystalloid solutions, such as normal saline. These fluids are inexpensive, stable, and logistically simple. The PREEVEnT trial hypothesizes that fresh frozen plasma (FFP) may be superior. This presents a direct and substantial economic pivot.

FFP carries a unit cost orders of magnitude higher than crystalloids. Its storage requires specialized freezing equipment, and its supply is dependent on a complex, donation-based supply chain with limited shelf life upon thawing. Widespread adoption of a plasma-first protocol would immediately increase per-patient acute care costs and place new operational pressures on hospital blood banks.

The countervailing economic argument resides in downstream cost offsets. The trial implicitly tests a "value-based resuscitation" model. If plasma demonstrably reduces the incidence of complications—such as abdominal compartment syndrome, acute respiratory distress syndrome, renal failure, and severe infections—the higher upfront product cost could be neutralized or outweighed. Savings would accrue from shorter intensive care unit stays, reduced need for organ support technologies, fewer surgical interventions, and decreased long-term morbidity. The economic analysis will hinge on this cost-complication trade-off.

Market patterns would inevitably shift. A positive trial outcome could generate a surge in demand for plasma products specifically earmarked for acute trauma resuscitation, potentially influencing regional blood product allocation, pricing structures, and inventory management strategies.

The Deep Science Entry Point: Targeting the Endothelial 'Black Box'

The trial’s acronym includes a critical, often overlooked component: "Endotheliopathy of Thermal Injury." This is not a secondary concern but the proposed mechanistic core of the intervention. Major burns induce a systemic endotheliopathy—a diffuse injury to the vascular lining. This damage increases capillary permeability, leading to profound edema, coagulopathy, and multi-organ dysfunction.

Traditional crystalloid resuscitation can exacerbate this endothelial leak, perpetuating the cycle of shock. The PREEVEnT trial’s innovative hypothesis is that plasma acts not merely as a superior volume expander, but as a pharmacologic intervention. Plasma contains a complex mixture of proteins, clotting factors, and adhesion molecules that may actively stabilize the damaged endothelial glycocalyx and modulate the systemic inflammatory response.

Success in the trial would validate endotheliopathy as a primary therapeutic target in critical trauma care. This, in turn, would redirect research and development investment. The focus would expand from blood product replacement to the development of synthetic or recombinant endothelial-targeted therapies, such as stabilized glycocalyx components or specific protease inhibitors. A new niche within the critical care pharmaceutical market could emerge, driven by the pathophysiology illuminated by this burn trial.

Market and Scientific Implications: A Protocol as a Catalyst

The PREEVEnT trial serves as a case study in how a focused clinical question can function as a catalyst for systemic change. Its results will be interpreted through two primary lenses.

From a market and operational perspective, a positive outcome would initiate a protracted transition period. Burn centers would become focal points for increased plasma consumption, necessitating revised contracts with blood suppliers and updated clinical logistics. Payers would require robust health-economic analyses to justify changes in reimbursement policies. Medical device and monitoring companies may see increased demand for technologies capable of assessing endothelial function or guiding targeted fluid therapy.

From a scientific perspective, the trial has the potential to consolidate a paradigm shift in trauma resuscitation, moving it from a purely hemodynamic model to a vascular-integrity model. Regardless of its primary endpoint result, the data generated on endotheliopathy will refine the understanding of burn pathophysiology. This knowledge will influence trial design for other forms of traumatic hemorrhagic shock, creating a ripple effect across the broader field of critical care medicine.

The final assessment of the PREEVEnT trial will therefore not be binary. It represents a pivotal investigation into whether a more biologically targeted, albeit more resource-intensive, intervention can redefine the standard of care and, in doing so, reshape the underlying economics and science of burn treatment.